Results 101 to 110 of about 16,120 (219)

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis

JACC: Basic to Translational Science, 2019
Summary: Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue.
Kathleen W. Zhang, MD, Keith E. Stockerl-Goldstein, MD, Daniel J. Lenihan, MD   +2 more
doaj   +1 more source

Pharmacological Interventions for Hereditary Transthyretin‐Related Amyloidosis With Polyneuropathy: Systematic Review and Network Meta‐Analysis

European Journal of Neurology, Volume 33, Issue 6, June 2026.
We conducted a systematic review and network meta‐analysis on pharmacological therapies for ATTRv‐PN. Gene‐silencing therapies were more efficacious than stabilizers for neurological and quality‐of‐life outcomes; there were no differences in serious adverse events.
Gonçalo S Duarte, Tiago Luís Gonçalves Neves Machado, Filipe B Rodrigues, Isabel Conceção, Davide Pareyson, João Nuno Marques Parracho Guerra da Costa, on behalf of the Task Force of the EAN/PNS Joint Guideline for the Management of Neurological Manifestations in Hereditary Transthyretin Amyloidosis   +6 more
wiley   +1 more source

Hereditary transthyretin amyloidosis: a case report

, 2022
BACKGROUND: Hereditary transthyretin amyloidosis is an uncommon multisystem disorder caused by mutation of the transthyretin protein, leading to peripheral neuropathy often with autonomic features, cardiomyopathy, or a mixed phenotype.
Bril, Vera, Fine, Nowell M., Lee, Angela, Delgado, Diego, Hahn, Christopher   +4 more
core   +1 more source

Speckle Tracking and Transthyretin Amyloid Cardiomyopathy

Arquivos Brasileiros de Cardiologia
Background: Amyloidosis is a disease caused by deposits of insoluble fibrils in extracellular spaces. The most common type of familial amyloidosis is mediated by mutation of transthyretin, especially Val30Met.
Alexandre Marins Rocha, Suzane Garcia Ferreira, Marcelo Souto Nacif, Mario Luiz Ribeiro, Marcos Raimundo Gomes de Freitas, Cláudio Tinoco Mesquita   +5 more
doaj   +1 more source

The Underscreening of Cardiac Amyloidosis in Patients With Pacemakers—A Single Centre Retrospective Audit

Journal of Cardiovascular Electrophysiology, Volume 37, Issue 6, Page 1372-1375, June 2026.
ABSTRACT Background Cardiac amyloidosis is commonly associated with cardiac conduction disease. We sought to determine the prevalence of advanced conduction disease requiring a pacemaker in patients with known cardiac amyloidosis to evaluate current screening practices among patients receiving pacemakers.
Peishan Cai, Timothy Scully, Jason Nogic, Kah Peck, Jithin Sajeev   +4 more
wiley   +1 more source

Palinacousis in amyloidosis: exploring the hallucinatory phenomenon in brain pathology—a case report

Journal of Medical Case Reports
Background Hereditary transthyretin amyloidosis, caused by transthyretin gene mutations, progresses with systemic impact and often presents peripheral neuropathy.
João Martins-Correia, Luísa Sousa
doaj   +1 more source

Treatment of transthyretin cardiac amyloidosis

Current Opinion in Cardiology
Purpose of review Tafamidis is currently the only approved disease-modifying treatment for ATTR-CM. However, there have been important developments in the treatment of ATTR-CM, as the results of two phase 3 trials were published and several other trials are in their final stages.
Bampatsias, Dimitrios, Wardhere, Abdirahman, Maurer, Mathew S.   +2 more
openaire   +2 more sources

Clinical Diabetic Peripheral Neuropathy: Can It Be Reversed? Arguments for and Against From a NEUROdiab Debate

Journal of the Peripheral Nervous System, Volume 31, Issue 2, June 2026.
ABSTRACT Diabetic peripheral neuropathy (DPN) is a prevalent and disabling complication of diabetes, yet whether established clinical DPN is reversible remains debated. At the 35th Annual Meeting of NEUROdiab, a formal debate examined arguments ‘for’ and ‘against’ the proposition that clinical DPN can be reversed.
Gordon Sloan, Shazli Azmi, Stephanie Eid, Maryam Ferdousi, Johan Røikjer, Zoltan Kender, Luca D'Onofrio, Eleni Karlafti, Brian Callaghan, Bruce A. Perkins   +9 more
wiley   +1 more source

A mutation in transthyretin gene in a Mexican patient leading to hereditary amyloidosis: a case report

Journal of Medical Case Reports
Background Transthyretin is a protein produced by the liver, and when normal, it carries out the role of transporting thyroid hormone and vitamin A in the body. Mutations in the gene that codes for this protein can cause it to misfold.
Muhammad Reebal Malik, Tarun Dalia, Zubair Shah   +2 more
doaj   +1 more source

Hereditary transthyretin amyloidosis (ATTRv)

Current Problems in Cardiology
Hereditary transthyretin (TTR) amyloidosis (ATTRv amyloidosis) is a devastating disease characterized by broad range of clinical manifestations, including predominantly neurological, predominantly cardiac, and mixed phenotypes. This wide phenotypic variability hindered timely disease diagnosis and risk stratification in the past, especially in ...
Filippos Triposkiadis, Alexandros Briasoulis, Randall C. Starling, Dimitrios E. Magouliotis, Christos Kourek, George E Zakynthinos, Efstathios K. Iliodromitis, Ioannis Paraskevaidis, Andrew Xanthopoulos   +8 more
openaire   +3 more sources